Angina pectoris
Drug research and approvals for angina pectoris: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 108 studies of angina pectoris are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 108
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 6
- Cardiopulmonary Exercise Active Health Cohort StudyNCT07935187 · Not reported · Peking University Third Hospital · starts May 11, 2026
- Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping PillsNCT07885462 · Phase 4 · Qilu Hospital of Shandong University · starts Nov 1, 2026
- Identification of Lesion Characteristics in Coronary Plaques Using Multimodality Intravascular Imaging and Novel…NCT07864025 · Not reported · Queen Mary University of London · starts Aug 19, 2026
- Analysis of Life-threatening ARrhythMias After Acute Coronary SyndromeNCT07824050 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jul 14, 2026
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeNCT07824323 · Phase 4 · Taipei Medical University Hospital · starts Aug 26, 2026
- First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary…NCT07811024 · Not applicable · Tonic Medical, Inc. · starts Aug 12, 2026
- BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac RehabilitationNCT07741396 · Not applicable · University of Illinois Chicago · starts Nov 2, 2026
- FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for KidsNCT07718464 · Not reported · Children's Hospital Medical Center, Cincinnati · starts May 27, 2026
- Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary SyndromeNCT07684742 · Phase 4 · Gyeongsang National University Hospital · starts Jul 1, 2026
Approved 15
- AtenololBeta-1 adrenergic receptor antagonist
- Candesartan cilexetilType-1 angiotensin II receptor antagonist
- MetoprololBeta-1 adrenergic receptor antagonist
- NadololBeta-1 adrenergic receptor antagonist
- NitroglycerinSoluble guanylate cyclase activator
- PropranololBeta-1 adrenergic receptor antagonist
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitor
- RanolazineSodium channel protein type V alpha subunit blocker
- AtorvastatinHMG-CoA reductase inhibitor
- Isosorbide mononitrateSoluble guanylate cyclase activator
- Isosorbide dinitrateSoluble guanylate cyclase activator
- DiltiazemVoltage-gated L-type calcium channel blocker
- AmlodipineVoltage-gated L-type calcium channel blocker
- IvabradinePotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
How its trials ended
485 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 114 whose ending is known, 52% met their primary endpoint, 12% missed it and 36% stopped early.
- Completed, result not reported17837%
- Status unknown12025%
- Ongoing7315%
- Met its primary endpoint5912%
- Stopped: other or unclear306%
- Missed its primary endpoint143%
- Stopped: enrollment or feasibility61%
- Stopped: funding41%
- Stopped: sponsor or business decision1<1%
| Dec 18, 2014 | A phase 2, randomized, double-blind, placebo controlled, parallel study of GS-6615 in subjects with chronic stable angina and coronary artery diseaseGS-6615 | Gilead Sciences | Pending |
| Oct 11, 2013 | The efficacy and safety of trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention. atpci study.Vastarel (trimetazidine) | Servier | Pending |
| Jul 19, 2013 | A prospective, randomized, double-blinded, active-control and unblinded standard of care (SOC) controlled study to determine the efficacy and safety of…AUTO-CD34+CELLS | Baxter International | Pending |
| May 22, 2017 | Ivabradine AccordIvabradine · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Nov 11, 2016 | Ivabradine ZentivaIvabradine · generic | Zentiva k.s. | EMA ↗ |
| Sep 8, 2015 | Ivabradine AnpharmIvabradine | "Anpharm" Przedsiębiorstwo Farmaceutyczne S.A. | EMA ↗ |
| Jul 8, 2008 | Ranexa (previously Latixa)Ranolazine | Menarini International Operations Luxembourg S.A. (MIOL) | EMA ↗ |
| Oct 25, 2005 | CorlentorIvabradine | Les Laboratoires Servier | EMA ↗ |
| Oct 25, 2005 | ProcoralanIvabradine | Les Laboratoires Servier | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA